Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
Kidney Disease
About this trial
This is an interventional treatment trial for Kidney Disease focused on measuring Alteplase; Hemodialysis Catheter; Occlusion; Renal Failure
Eligibility Criteria
Inclusion Criteria:
A patient will be deemed eligible for inclusion in the study if he/she:
- Is ≥ 18 years of age,
- Is receiving HD for chronic renal failure using permanent HDC that is inserted in any of the following sites: internal jugular, subclavian, or femoral veins
- Has no medical contradiction for tPA management of partially or fully occluded HDC.
In addition, only the first occlusion event that requires tPA administration for a single catheter will be included. However, each new catheter insertion for the same patient during the study will be treated as a new event. That is, a single patient may be randomized more than one time if he/she experiences the insertion of more than one catheter during the course of the study
Exclusion Criteria:
- Pregnant women
- Patients who received ≤ 7 dialysis treatment sessions or have been on dialysis for less than 15 days
- Patients who had contraindications, allergies, or history of intolerances to tPA will be excluded
Sites / Locations
- Windsor Regional HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
1.0 mg alteplase (tPA)
2.0 mg alteplase (tPA)
1.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
2.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat